Study identification

PURI

https://redirect.ema.europa.eu/resource/49527

EU PAS number

EUPAS49365

Study ID

49527

Official title and acronym

Five years of COPD primary care: Patterns of management of high-risk COPD and opportunities for optimising care in Australia 2015-2019 (COPD Opportunity Analysis in Australia)

DARWIN EU® study

No

Study countries

Australia

Study description

The main aim for this “Opportunity Analysis” is to assess the management of patients with high-risk COPD over 5 years in Australian primary care and describe opportunities for treatment optimisation in line with the CONQUEST Quality Standards, over this period. The objectives per quality standards are: 1. Assess whether undiagnosed patients who potentially have high-risk COPD are actively and promptly identified in Australian primary care. 2. Assess whether high-risk patients with newly diagnosed COPD receive a proper assessment and quantification of future risk of exacerbations and cardiac events within 12 months of diagnosis. 3. Assess whether pharmaceutical and non-pharmacological therapy is provided to patients with high-risk COPD within 12 months of meeting criteria for high-risk COPD. 4. Assess whether high-risk patients diagnosed with COPD are followed up appropriately over a 12m period following baseline assessment

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Optimum Patient Care Australia
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable